subject area of
- CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis Academic Article
- Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum Academic Article
- Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data Academic Article
- Lack of Health-Related Quality of Life and Patient-Centered Outcome Measures in RCTs Conducted for Diabetes Pharmacotherapy: SGLT-2 receptor inhibitors as an example Academic Article
- Non-Severe Hypoglycemia Risk Difference Between Sulfonylurea and Sodium-Glucose Cotransporter-2 Inhibitors (Sglt2-I) as an Add-On to Metformin in Randomized Controlled Trials Academic Article
- Patient data from routinely collected medical records complement evidence from SGLT2 inhibitor outcome trials Academic Article
- Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes–2015 Interim Update Academic Article
- The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels Academic Article